Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market
Rhea-AI Summary
Marijuana Inc. (OTCPINK: MAJI) has acquired 100% of Exousia AI in a cash and stock transaction, issuing 47 million restricted shares to Ludwig Enterprises with specific lock-up features tied to NASDAQ uplisting. The deal includes assuming liabilities under $75,000 and a $100,000 note.
The acquisition brings worldwide licensed technology for plant-based and human-derived exosomes, including ongoing studies for Glioblastoma treatment and planned studies in dermatology and dental markets. The company will manufacture and sell exosomes for nutraceutical and dermatology markets, targeting the rapidly growing cosmeceuticals sector.
The exosome skincare market is projected to grow from $310 million in 2025 to $633 million in 2033, with a 10% compound annual growth rate. A 30-day treatment currently sells for $400 per vial. The company plans to expand its oncology studies and potentially license its technology to drug manufacturers for enhanced chemotherapy treatments.
Positive
- Acquisition includes worldwide license for exosome technology
- Access to growing skincare market projected to reach $633M by 2033
- High-margin product with $400 per vial pricing for 30-day treatment
- Ongoing promising studies in Glioblastoma treatment
- Potential for additional revenue through pharmaceutical licensing
Negative
- Assumes liabilities under $75,000
- $100,000 note payable to Ludwig
- Significant share dilution with 47 million new shares
- Uplisting requirement for share restriction removal
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Pursing commercial applications in skincare serving a growing market of
The 47,000,000 shares being issued are restricted shares with certain lock-up features. The legend cannot be removed until six months AFTER Exousia Pro has completed its up-listing with NASDAQ or an equivalent exchange. The Company further agreed to assume liabilities under
Exousia AI is a leading
Exousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets. The OTC exosome market, known as cosmeceuticals, is rapidly expanding due to consumer demand for antiaging and regenerative skincare solutions. A 30-day treatment for skin and hair sells for
Exousia is in talks to license several other patents using Exosomes, which, once secured, will allow the Company to expand its oncology studies beyond GBM.
When Exousia Pro proves its technology enhances current chemotherapy drugs on the market, it can contact the drug manufacturers and license the tech for use in their drug therapy.
"The exosome market is in its infancy, but poised for explosive growth, as evidence by a surge of promising studies," said CEO of Marijuana Inc., Michael Sheikh. "Mounting research points to the vast therapeutic potential of exosomes, highlighting their capacity to precisely target diseases while minimizing side effects. Investors may not fully appreciate the dominance of monoclonal antibodies, which now lead the pharmaceutical market in revenue. This success stems from their ability to target diseased cells, often delivering therapeutic payloads directly where needed. Every major pharmaceutical company is actively developing monoclonal antibody drugs, driven by the universal desire for treatments that alleviate symptoms without causing new ones."
"Exosomes represent the next generation of targeted therapies, surpassing monoclonal antibodies in several key aspects. They offer significant cost advantages in production, the capacity to deliver larger and more complex payloads, including sensitive molecules like DNA, and a broader range of applications. Importantly, exosomes also mitigate the risk of off-target effects and immune reactions often associated with current monoclonal antibody treatments. This would be a key selling point in the event of licensing discussions. Exosomes embody an elegant evolution in biotechnology, and Exousia Pro is committed to spearheading their commercialization and therapeutic development."
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
View original content:https://www.prnewswire.com/news-releases/marijuana-inc-completes-acquisition-of-exousia-ai-and-enters-expanding-exosome-market-302342570.html
SOURCE Marijuana Inc.